surotomycin

Surotomycin is an investigational oral antibiotic belonging to the cyclic lipopeptide class. It was developed for the treatment of *Clostridioides difficile* infection (CDI) and other Gram-positive infections. Surotomycin exhibits a fourfold greater *in vitro* potency than vancomycin against *C. difficile* and other Gram-positive bacteria, with minimal impact on Gram-negative organisms of the intestinal microbiota. Its mechanism of action involves modulation of bacterial cell membranes, leading to antibacterial effects while sparing much of the normal gut flora. Surotomycin was originally developed by Cubist Pharmaceuticals and later by Merck & Co following their acquisition of Cubist. Despite promising early results, development was discontinued after phase III trials due to unfavorable efficacy data and commercial considerations[1][2][3][4][5][7].

Other names

surotomycin